TSHA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Taysha Gene Therapies Inc (TSHA) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 to invest. The stock shows strong growth potential based on its technical indicators, positive analyst sentiment, and improving financial performance. Despite insider selling, hedge fund interest and a low put-call ratio suggest bullish sentiment. The lack of recent news or congress trading data does not detract from the positive outlook.
The stock's MACD is positive (0.201), indicating bullish momentum, and the moving averages (SMA_5 > SMA_20 > SMA_200) confirm an upward trend. RSI at 67.617 is neutral, suggesting the stock is not overbought. Key resistance levels are at 6.551 and 7.124, while support levels are at 5.625 and 4.699.
Hedge funds have significantly increased their buying activity (up 649.63% last quarter). Analysts have raised the price target to $17 and maintain a Buy rating, citing positive trial progress and upcoming data releases. Financial performance shows significant revenue growth (up 171.27% YoY) and improved net income and EPS.
Insiders have increased selling activity by 11,823.54% in the last month, which could indicate caution. Additionally, the stock is down slightly (-0.16%) in pre-market trading.
In Q4 2025, revenue increased by 171.27% YoY to $5,485,000. Net income improved by 48.26% YoY to -$27,851,000, and EPS rose by 14.29% YoY to -0.08. Gross margin remained at 100%, indicating efficient cost management.
Analysts are bullish on TSHA, with Canaccord raising the price target to $17 from $14 and maintaining a Buy rating. Positive trial updates and upcoming data releases are key drivers for the optimism.
